© Copyright Nostre Net
According to MRFR analysis, the global downstream
processing market is expected to register a CAGR of~16.09% from 2021 to 2027and
hold a value of ~USD 61,174.53million by 2027.
Downstream processing refers to the series
of operations required to derive pure and homogeneous protein products from
biological materials such as cells, tissue culture fluid, or plant tissues.
There is a high demand for the end products extracted by downstream processing,
owing to the increasing applicationsin biopharmaceutical products. Thus, the downstream
processing market is anticipated to observe significant growth during the
forecast period.
Many market players are dominating the
global downstream processing market. The prominent players are involved in
strategic agreements,new product launches& developments,joint ventures,
partnerships, collaborations, mergers & acquisitions, geographic
expansionto sustaintheir market positions.For instance, in March 2021, Thermo
Fisher Scientific, Inc. (US) announced that more than USD 600 million would be
invested to expand its bioprocessing production capabilities through 2022 to
meet short-term demands related to COVID-19 as well as long-term efforts to
improve new vaccines and biologics for other conditions.
Segmentation
The global downstream processing market has
been segmented into technique, product, application, and end user.
By technique, the market has been
segregated into cell disruption, solid-liquid separation,
clarification/concentration, downstream purification techniques, and
formulation. The purification techniques segment is further sub-segmented into
ion exchange, affinity exchange, hydrophobic interaction, size exclusion
chromatography, and others. The purification techniques segment held a
significant share of the market in 2020, as it isone of the vital steps in
downstream processing and has high product differentiation.
Based on the product, the global downstream
processing market has been classified as chromatography columns &resins,
filters, membrane adsorbers, and others. The chromatography columns
&resinsis one of the most widely used product andwasestimated to bethe
largest segment in 2020.
Based on application, the downstream processing
market is segmented into antibiotic production, hormone production, antibodies
production, vaccine production, and others. Antibiotic productionis one of the
vital applications owing to increasing infectious diseases. Furthermore, the
ongoing pandemic has created a huge demand for vaccine production globally
which further supports the growth of the market.
Based on the end user, the downstream
processing market is segmented into biopharmaceutical manufacturers, contract
manufacturing organizations, and others. The biopharmaceutical manufacturers
segment held the largest market share in 2020 due to increased R&D
activities and production of biologics at a largescale, along with the rapidly
growing biopharmaceutical industry.
Key Players
Some of the in the global downstream
processing market players are Thermo Fisher Scientific Inc. (US), Sartorius
Stedim Biotech S.A. (France), Merck Millipore (Germany), Danaher Corporation
(US), 3M Company (US), Boehringer Ingelheim (Germany), Lonza Group AG
(Switzerland), Eppendorf AG (Switzerland), Corning Incorporated (US), and Asahi
Kasei Corporation (Japan).
Regional Analysis
By region, North America is anticipated to
dominate the global downstream processing market, owing to well-established
research organizations involved in research activities, the presence of a high
number of contract manufacturing organizations (CMOs), and the presence of a
largenumber of pharmaceutical and biopharmaceutical companies. Moreover, the
rise in R&D investments by public and private players in the healthcare
sectorfurther drives the market growth.
On the other hand, the European downstream
processing market is driven by rising R&D expenditure by biopharmaceutical
companies, increasing investments in the R&D sector, and the presence of
key market players. For instance, in November 2019, Thermo Fisher Scientific,
Inc. (US) announced that it is investing nearly USD 24 million in its Scotland
site to expand global bioproduction capabilities with additional large-volume
liquid manufacturing capacity for cell culture media.
Asia-Pacific is anticipated to be the
fastest-growing market in the region over the assessment period due to growing
and improving healthcare infrastructure, the establishment of research
organizations, and increasing investments in biotechnology. In addition,
factors such as the growing investments by key market players and the rapidly
developing pharma and biopharma sector in the region are further driving the
market.For instance, in April 2021, Asahi Kasei Corporation, a solution
provider to the biologics manufacturing industry, expanded its business in
China with the launch of Asahi Kasei Bioprocess (Shanghai) Co., Ltd (AKBC).The
launch of AKBC facilitates business expansion in China by localizing inventory
management and order processing for shorter delivery times.
Furthermore, the growth of the market in
theRest of the World is attributed to the booming biotechnology sector and
advancements in chromatographic techniques inthe region.
About US:
Market Research Future (MRFR), enable customers to
unravel the complexity of various industries through Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Molecular modelling is a strategy that involves
computational techniques that integrates creation, manipulation, and
representation of molecular structures. Based on this technology, a lot of drug
can be developed. This process enables scientists to run various simulations
that can ensure better results for the global drug development market. The
global molecular
modelling market is expected to cross USD 1,617.80 million a CAGR of 15.93%
during the forecast period 2027. Market Research Future (MRFR) discloses
possibilities that can be explored well in the future to ensure strong growth
in the coming years.
Various factors like hike in research-related investments,
growing impact from pharmaceuticals to discover new drugs, technologies to
develop personalized drug, better healthcare-related investments, growing cases
of chronic disease, hike in budgets for healthcare sector, and other are
expected to influence the global molecular modelling market. The burgeoning
biosimilars and biologics industry is expected to take the market further ahead
in the coming years.
Segmentation:
Product, application, and end-users are segments that have been
included in the global molecular modelling market. This analysis is expected to
provide in-depth analysis of various factors that can be used later to garner
more profits in the coming years.
By product, the molecular modelling market comprises software
and services. The software segment is generating substantial revenue and is
expected to climb up with a 13.55% CAGR. But the services segment is expected
to register the fastest CAGR of 18.64% within the same time frame.
Based on the application, the global molecular modelling
market can be segmented into drug development, drug discovery, and others. the
drug development segment can step ahead with 13.26% CAGR during the forecast
period. The drug discovery segment is deemed to register the fastest CAGR of
17.30% over the assessment period.
By end-users, the molecular modelling market comprises
research centers & academic institutions, pharmaceutical &
biotechnological companies, and others. The pharmaceutical and biotechnological
companies are expected to register a 13.84% growth during the forecast period,
whereas, the research centers and academic institutions can post a CAGR of
19.16% during the review period.
Competitive Landscape:
The global molecular
modelling market players are Schrödinger, LLC, Cresset, Acellera Ltd.,
BioSolve-IT, Optibrium, Chemical Computing Group, Simulations Plus, Inc.,
Cambridge Crystallographic Data Centre OpenEye Scientific Software, Certara,
L.P, Dassault Systèmes, and others. MRFR included these companies and profiled
them for a better analysis of the global process. Such a report also includes
various strategic moves taken by these companies. These moves are merger,
acquisition, collaboration, and other methods.
Regional Analysis:
Region-wise analysis of the global molecular modelling
market has four specific regions under its coverage. These regions are the
Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA).
The report is all set to provide better demographic analysis to assist in the
exploration of several possibilities that can impact the market growth in the
future.
Technical superiority, robust infrastructure, high expenditure
capacity, better research & development projects, and other
healthcare-related initiatives are expected to provide strong traction to the
regional market. The Americas is a region that includes two regions, North and
South America. North America has better market scenario than South
America.
Europe is sharing similar features like that of North
America. These two regions are known for their research and development
projects where development of new products and innovations are quite expected.
The region is following North America closely in terms of market valuation.
Several countries like the UK, France, Germany, and others are expected to
promote the regional market.
The APAC market is expecting strong growth in the coming
years with assistance from the hike in the market valuation of China, India,
Thailand, Singapore, and others.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity
of various industries through Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research
(CFR), and Market Research & Consulting Services.
According to MRFR analysis, the global biopharmaceutical
excipients market is expected to register a CAGR of~6.8% from 2021 to 2027 and
is expected to hold a value of ~USD 3,114.6 million by 2027
The global biopharmaceutical excipients market is driven by
several factors, such as increasing demand for oral formulations across the
globe, rising demand for customized medicines, and an increasing geriatric
population. Other factors such as increasing patients with chronic ailments coupled
with growing life expectancy are driving the production of biopharmaceuticals.
In addition, increasing stress, back pains, body aches, and headaches has
augmented the demand for topical type formulation, accelerating the market
growth.
The industry players focus on expanding their global
footprint by strategic partnerships, investing in some company’s stock,
acquisitions, and product launches. For instance, in February 2020, Re Form
Biologics (US) partnered with Millipore Sigma (US) to commercialize excipients
used in biotherapeutics. In August 2019, LBB Specialties (US) announced the
strategic partnership with MEGGLE (Germany)to expand its excipient distribution
channel across the US. In December 2018, Roquette (France) bought a majority
stake in excipient producer Crest Cellose (India) that enabled the company to
expand its product portfolio and presence in the Indian generic pharmaceutical market.
Furthermore, the prominent players focus on new developments, employee
satisfaction, the transformation of their research wings, and expanding their
distribution network. These factors will augment the market growth and will
increase the product demand in the forecast timeline.
Key Players
Some of the in the global biopharmaceutical
excipients market players are Merck KGaA (Germany), Colorcon (BPSI Holdings
Inc) (US), BASF SE(Germany), Associated British Foods plc (UK), Signet
Excipients Pvt. Ltd (IMCD) (Netherlands), Sigachi Industries Limited
(Hyderabad), Spectrum Chemical Manufacturing Corp. (US), Roquette Frères (France),
Clariant (Switzerland), DFE Pharma (Germany), J. Rettenmaier & Söhne Gmbh +
Co Kg (Germany), and Evonik Industries AG (Germany).
Regional Analysis
North America is projected to dominate the biopharmaceutical
excipients market due to the growing adoption of the latest drug manufacturing
technologies, increasing chronic diseases, and expansion of production
capabilities of the industry players across the region. In addition, high investments
were made in the development of new excipient variants to advance the product
portfolio. Furthermore, the key players are involved in collaborations,
mergers, and R&D activities that propel market growth.
Europe embraces the second-largest position in the
biopharmaceutical excipients market due to growing investments in the
pharmaceutical sector and increasing production capacity across the region. In
addition, the region experienced high demands for pharmaceutical products.
Moreover, countries such as Germany, Italy, the UK, France, and Spain have
invested huge amounts in the manufacturing of new vaccines.
Asia-Pacific is anticipated to be the fastest-growing
regional market over the projected timeline due to the rising investment in
pharmaceutical research and production facilities, increasing consumption of medicines,
and supportive government alliances and subsidy schemes. In addition, the
availability of highly skilled research employees and an economical workforce
is creating opportunities for the industry players.
Furthermore, the market in the Rest of the World is gaining
importance due to the rising number of investors, growing geriatric population
in countries such as Chile and Argentina, and expansion of the pharmaceutical
market across Latin America. However, the availability of counterfeit
pharmaceutical goods is hampering the biopharmaceutical excipient market. The
pharmaceutical companies aim atinvesting in the Middle East & Africaregion
owing to its technologically advanced labs and other research infrastructures.
Countries such as Saudi Arabia and the UAE are hiring employees throughout the
globe to advance their pharmaceutical market.
Segmentation
The global biopharmaceutical excipients market is
categorized into product and formulation. Based on the product category, the
market has been segregated into solubilizers & surfactants/emulsifiers,
polyols and carbohydrates, and specialty excipients. The carbohydrates segment
is expected to hold a considerable share of the market in 2021. Increasing
R&D activities for the development of lipid and protein excipient-based
corona vaccines is fueling the market demand. In addition, the high demand for
carbohydrate-based medicines for the infant segment is propelling the
biopharmaceutical excipient market.
Based on formulation, the global biopharmaceutical excipients
market has been classified as oral, topical, and injectables. The oral segment held
the major share in 2020 due to the easy intake procedure and availability of
oral medicines throughout the hospitals and retail stores. Additionally, the
demand for oral and topical formulations is accelerating due to the growing
preference for on-the-go treatment and ambulatory treatment services coupled
with increasing cases of trypanophobia.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity
of various industries through Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research
(CFR), and Market Research & Consulting Services.
Tissues, cell lines, and cells are tested,
characterized, stored, and collected by the cell banking outsourcing industry.
These activities are carried out to aid in the production of biopharmaceuticals
as well as research and development activities, ensuring minimal side effects
and great efficacy. The technique for cell preservation entails initially
proliferating cells, which subsequently multiply into a large number of
identical cells, which are then stored in cryovials for future use. The
production of regenerative medicine is essentially based on the use of cells.
During the projection period of 2021 to 2027, the cell banking outsourcing
market is estimated to reach USD 9476.9 million, growing at a CAGR of 15.6%.
Market Trends
During the forecast period, the cell
banking outsourcing market is expected to rise due to an increase in the
number of cell banks around the world. Another factor projected to drive market
growth is the growing number of applications of cell-based products for
research and therapeutics. Furthermore, a jump in the number of start-ups
focusing on cell-based therapeutics and vaccine production is expected to drive
market expansion. Similarly, the growing emphasis on regenerative and
customized medicine is expected to fuel growth in the cell banking outsourcing
industry. Due to well-established healthcare infrastructure, large patient
populations, and significant healthcare expenditures, several key businesses
focus on tailoring products and services to the American and European markets.
There are no public cord blood banks in Africa, and importing cord blood units
from other countries is prohibitively expensive for most patients. With
first-to-market advantage, launching subsidiaries in developing regions can be
advantageous.
Furthermore, as the prevalence of
oncology-related diseases and other infectious chronic diseases rises,
cytological R&D, in which cell banking plays a key role, is predicted to
develop. Over the projected period, R&D for commercialization of novel
characterisation and cryopreservation procedures is expected to significantly
boost profitable business potential.
Concerns over sharing of crucial clinical
information discovered during the donor screening process, as well as issues
around the techniques used to get informed permission from potential cord blood
donors, are limiting the expansion of the cell banking outsourcing business.
Competitive Dynamics
The notable cell
banking outsourcing market players are CordLife (Singapore), Cleancells
(France), Charles River Laboratories (US), BSL Bioservice (Germany),
BioReliance (US), Sartorius (Germany), Covance (US), LifeCell International
Pvt. Ltd. (India), Goodwin Biotechnology Inc. (US), GlobalStem Inc. (US),
Cryo-Cell International Inc. (US), Lonza (Switzerland), PX’TherapeuticsSA
(France), Wuxi Apptec (China), and the SGS Life Sciences (Switzerland).
Segmental Analysis
The global cell banking outsourcing market
is divided into three categories: bank, cell, and application.
The market has been classified into three categories
based on bank type: master cell banking, working cell banking, and viral cell
banking. Because of its widespread utility, master cell banking is expected to
have the largest market share in the worldwide cell banking outsourcing market.
The cell banking outsourcing market has
been divided into stem cell banking and non-stem cell banking based on cell
type. Because of its growing uses in regenerative medicine, the stem cell
banking sector is expected to have the greatest market share in 2021.
Cell bank storage, cell bank preparation,
and bank characterization and testing are the application segments of the cell
banking outsourcing market.
Regional Overview
North America, Europe, Asia-Pacific, and
the rest of the globe are the regions that make up the market.
Because of the greater adoption rates of
novel technologies for the manufacturing of vaccines and therapeutic
antibodies, North America is expected to have the greatest market share in
2021. Furthermore, the presence of various biopharmaceutical businesses in the
region is expected to drive the cell banking outsourcing market in North
America to new heights in the near future. North America is also likely to be a
lucrative market due to the large number of research and development
initiatives related to cytological inquiry for proteomics, genomics, and
medication and vaccine development currently underway in the region. The
growing demand for vaccines and biopharmaceuticals is expected to boost this
region's growth.
The growing prevalence of leukemia in
European countries is likely to drive the region's cell banking outsourcing
industry forward. Furthermore, the region's cell banking outsourcing market is
benefiting from an increase in the number of clinical trials and associations
dedicated to discovering a cure for incurable diseases.
About US:
Market Research Future (MRFR), enable customers to
unravel the complexity of various industries through Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Cellulite
Treatment Market Overview by Treatment Procedure, Cellulite, End Use and
Region Forecast to 2027. Cellulite
production has swelled in recent years due to poor nourishment, static
postures, dehydration, inflammation, eating habits, alcohol intake, among other
factors. The MRFR report predicts that the market will earn a revenue level of USD
1,086.44 million at a CAGR of 8.97% by 2027.
Most
corporate employees with cellulite are working on their wellbeing and fitness
to amplify their productivity. Resultantly, many firms are partnering with
clinics and hospitals to help their staff stay healthy.The cellulite treatment market is
motivated by the tremendous influx of female population in metro centers due to
employment as younger employees are more health-conscious and press for a
better physique to avoid medical problems.
The foremost players in the cellulite
treatment market areNubway (China), Zimmer
Aesthetics (Germany), Skinrex Co., Ltd. (South Korea), Cymedics (Germany),
Tanceuticals, LLC. (US), Cynosure, Inc. (US), Inceler Medikal Co. Ltd.
(Turkey), Syneron Medical Inc (US), Hologic Inc. (US), Cutera (US), Beijing
Sincoheren S & T Development Co., Ltd, (China), Candela Medical (US), and
Merz Pharma GmbH & Co. KGaA (Germany).
Segmental
Analysis
The
segmentation of the cellulite treatment market has been conducted based on
cellulite type, treatment procedure, region, and end use. The cellulite
treatment market is divided into three segments based on end use: specialized
dermatological clinics, hospitals, and ambulatory surgical centers. The cellulite treatment market has been
segmented based on treatment procedures into minimally invasive, non-invasive,
and topical treatment. The cellulite treatment market has been divided into
three segments based on cellulite type: soft cellulite, hard cellulite, san
francisco cellulite treatment and edematous cellulite. The region segment of
the cellulite treatment market includesNorth America, Asia-Pacific, Europe, and
other important regions.
Detailed
Regional Analysis
The
regional assessment of the cellulite treatment market researchreport includes North America, Asia-Pacific, Europe, and
other important regions. North America will have the greatest cellulite
treatment market share in 2020, owing to well-established product development
research groups, the availability of novel treatment products, the consumption
of unhealthy diets, and the significant desire for the sculpted figure. The
primary players are expanding their operational facilities across the region,
collaborating in collaborations and partnerships, and launching new products to
drive economic interests. Due to the transformation of healthcare
infrastructure, the construction of R&D facilities, and increased awareness
about body contouring and physical wellness, the Asia-Pacific cellulite
treatment market is estimated to be the fastest regional market.
Competitive
Analysis
The continuation of occasional lockdowns in
numerous regions may cause the market expansion to be hampered if resources
such as labor and supply chains are severely impacted. The global market is
expected to diversify in operational techniques as innovative models for
operation and delivery are implemented. Government assistance is expected to
support worldwide market development in the next years. Due to the return of
COVID cases in many locations, the market may exhibit constrained growth. It is
projected that the emphasis on accumulating reserves of resources to deal with
unexpected crises would impact future market trends. Market developments and
research are expected to generate attractive growth opportunities in the next
years. The reliance on online commerce for sales is expected to increase
significantly during the forecast period, prompting market stakeholders to
invest more in its growth.
About US:
Market Research Future (MRFR), enable customers to
unravel the complexity of various industries through Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
The global dental
industry market is projected to reach approximately USD 60.37 billion by
2030, at a CAGR of 6.9% from 2022 to 2030. Dentistry, also known as oral
medicine and dental medicine, is a branch of medicine that consists of the
study, diagnosis, prevention, and treatment of diseases, disorders, and
conditions of the oral cavity, normally in the dentition but also the oral
mucosa, and of adjacent and related structures and tissues, mainly in the
maxillofacial area. Though primarily associated with teeth among the general
public, the field of dentistry or dental medicine is not limited to teeth but
also includes other aspects of the craniofacial complex, including the
temporomandibular joint and other supporting anatomical structures, and
lymphatic, vascular, muscular, and nervous systems. The rising healthcare
expenditure has boosted the demand for the dental industry, thereby
accelerating market growth. Rising geriatric population is anticipated to drive
the demand for the dental industry further
Segment Analysis
Global Dental Industry Market based on the product has been
segmented into discipline, consumables, and end user. The global dental
industry market, by discipline, has been segmented into
endodontics, restorative
dentistry, prosthodontics, periodontics, orthodontics, cosmetic
dentistry, oral surgery, maxillofacial surgery. On the basis of
consumables, the market is bifurcated into resin composites, dental
biomaterial, dental aesthetic, endodontic supplies, gingival
retraction material, whitening material, denture
adhesive, dental impression, dental burs, dental syringe. On the
basis of end user, the market is bifurcated into hospitals &
clinics, specialty dental centers, and dental academic and research
institutes.
Key Players
MRFR recognizes the following companies as the in the global
dental
industry market Players — 3M (US), Allergan plc (US), Coltene Group
(Switzerland), Dentsply Sirona (US), and Henry Schein, Inc (US).
Regional Analysis
Global Dental Industry Market, based on region, has been
divided into the Americas, Europe, Asia-Pacific, and the Middle East &
Africa.
The Americas has been segmented into North America and Latin
America, with the North America market further divided into the US and Canada.
The Americas dominated the market in 2019 and is likely to continue to command
during the assessment period. This is due to the rising prevalence of dental
disorders, leading to the high demand for dental procedures and a preventive,
restorative, and surgical device for dental care. Additionally, the growing older
population is also helping in the growth of the dental industry market.
According to the Administration for Community Living, the population aged 65
and above increased from 37.2 million in 2006 to 49.2 million in 2016 in the
Americas. Hence, a large patient pool suffering from tooth decay and a rising
geriatric population are expected to boom the market growth in the Americas.
The European dental industry market has been divided into
Western Europe and Eastern Europe. The Western Europe dental industry market
has further been classified into Germany, France, the UK, Italy, Spain, and the
rest of Western Europe. Europe is the second-largest region in the dental
industry as dental and oral diseases are among the major concerns for
Europeans, which ultimately shows the need for better treatment. Hence, the
demand for dental devices is increasing in the EU region, which is augmenting
the growth of the dental device market. The availability of advanced diagnostic
and therapeutic options is also playing an important role in the growth of this
market. Ongoing research by medical research laboratories and academic
institutes is leading to new developments in the effective cure of dental
disorders.
The Middle East & Africa dental industry market is
segmented into the Middle East and Africa. The increasing number of companies
and subsidiaries in the region drives the dental industry and the
ever-increasing demand for dental cosmetic surgeries in EMEA. Furthermore, the
lack of oral healthcare awareness in Saudi Arabia is a major concern among
consumers in the country, especially among children.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity
of various industries through Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research
(CFR), and Market Research & Consulting Services.
The surgical instrument tracking system market is predicted
to grow at 11.5% CAGR expected to reach USD 503.5 Million between 2022-2030,
reveals the new Market Research Future (MRFR) report. Surgical instrument
tracking systems are incredibly effective systems that assist healthcare
providers. It basically comprises of software, hardware, and service. The
specialty of this tracking system is it can work wonders in enhancing staff
productivity, enhancing patient safety, and decreasing case delays.
Various factors are propelling the surgical
instrument tracking system market growth. Some of these factors include
growing need for better patient care and inventory management, unique device
identification regulations by FDA, growing prevalence of retained surgical
instrument, increasing number of surgeries, growing need for inventory
management, growing use of medical devices, growth of surgical instruments, and
investments by public and private hospitals, and technological
advancements.
On the flip side, the unreliability of barcode systems,
lengthy investment cycles, budgetary limitations, and huge system costs are
factors that may hamper the surgical instrument tracking system market growth
over the forecast period.
Market Segmentation
The Market Research Future report provides a complete
segmental analysis of the surgical instrument tracking system market based on
types, end users, and component.
Based on type, the surgical instrument tracking system
market is segmented into radio frequency identification, barcode tracking,
electronic tracking, and others. Of these, the barcode tracking segment will
have the largest share in the market over the forecast period. It is the most
extensively used, especially in the medical devices industry, which is adding
to the growth of the segment.
Based on end users, the surgical instrument tracking system
market is segmented into laboratories, research facilities, clinics, hospitals,
and others. Of these, the hospitals segment will dominate the market over the
forecast period. This is owing to the high inflow of patients in hospitals
compared to others. Moreover, hospitals use more instruments and equipment and
perform a higher number of surgical procedures compared to other forms of
healthcare providers.
Based on the component, the surgical instrument tracking
system market is segmented into services, software, and others. Of these, the
software segment will lead the market over the forecast period owing to the
introduction of new software applications and frequent need for upgrades.
Key Players
Major profiled in the surgical
instrument tracking system market players include Key Surgical (US), Mobile
Aspects, Inc. (US), TGX Medical Systems (US), Infor (US), STANLEY Healthcare
(US), Censis Technologies, Inc. (US), B. Braun Melsungen AG (Germany),
Dickinson and Company (US), and Becton. Key players have incorporated different
strategies to create a foothold in the market, such as partnerships/joint
ventures, R&D activities, mergers and acquisitions, product innovations,
and more.
Regional Analysis
Based on the region, the surgical instrument tracking system
market report covers the latest trends and growth opportunities across North
America, Europe, the Middle East and Africa, and the Asia Pacific. Of these,
North America will have the lion’s share in the market over the forecast period
chiefly due to the increasing adoption of surgical instrument tracking systems,
highly developed healthcare infrastructure, accessibility of advanced products,
and the UDI regulations by the FDA. The US is the chief contributor in the
region.
The surgical instrument tracking system market in Europe is
predicted to have the second-largest share in the market over the forecast
period. This is chiefly on account of growing private funds, government
initiatives, the emergence of better and high-quality healthcare
infrastructure, cost advantage, rising healthcare sector privatization, and
rising medical tourism.
The surgical instrument tracking system market in the APAC
region is predicted to grow at the fastest pace over the forecast period.
Factors aiding the growth of the surgical instrument tracking system market in
the region include rapidly evolving healthcare infrastructure, increasing
geriatric population, healthcare industry from other regions shifting to APAC,
and better health management. China, as well as India, are the leading
contributors in this region.
The surgical instrument tracking system market in the MEA is
predicted to have a small share in the market over the forecast period.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity
of various industries through Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research
(CFR), and Market Research & Consulting Services.
According to MRFR analysis, the Global Life
Sciences BPO Market is expecting to grow at a CAGR of 13.60% and by the end
of the period in 2027, the market is expected to reach a final market value
worth USD 427.78 billion. Global Life Sciences BPO Market is driven by several
factors, such as rising need for drug research, clinical data management
trials, increasing cost of drug development, new product launches and
government initiatives, increased pressure from regulatory agencies to adopt
various techniques to minimize the costs involved for the successful
introduction of a drug in the market.
A lot of market players are dominating the global life
sciences BPO market. The prominent players are involved in strategic
agreements, product launches, and joint ventures to sustain their market
positions. For instance, in June 2018, Laboratory Corporation of America
Holdings (US) acquired Sciformix Corporation, a Covance company (US), to offer
pharmacovigilance and regulatory solutions to biopharmaceutical and medical
device companies.
Regional Analysis
On a regional basis, the Americas is anticipated to dominate
the global life sciences BPO market, owing to the factors such as
well-established healthcare sector, presence of ample biotechnology and
pharmaceutical companies, new technological advancements in life sciences
industry, major giants in the market involved in merger & acquisition, and
new product innovation. Technologies such as Artificial Intelligence (AI),
Machine Learning (ML) are playing a significant role in the life science BPO
industry, while significantly reducing costs involved with mapping highly
complex studies. Companies are adopting these technologies for drug discovery.
For instance, in June 2019, Navitas Life Sciences (US) in partnership with
ThoughtSphere (US) Company adopted AI and ML technologies to deliver
unparalleled data collection.
On the other hand, Europe is expected to hold the
second-largest position in the global life sciences BPO market, due to the
favorable regulatory scenario to support the outsourcing process in the life
sciences industry. For instance, in 2020, UK Medicines and Healthcare products
Regulatory Agency (MHRA) and the European Medicines Agency (EMA) issued
guidance on how investigators and sponsors should manage clinical trials during
the outbreak. Such moves are set to increase the European life science
industry.
Asia-Pacific is anticipated to be the fastest-growing region
over the assessment period due to the rising demand for outsourcing in the life
science industry, and the rising importance of safety & security of
products. Initiatives by the government such as the introduction of ICD-10 standards
that capture the inpatient procedures has supported the rising adoption of
electronic health records (EHR), electronic laboratory notebook (ELN) in the
life sciences industry. These digital platforms enable the rapid growth of the
back-end payer and provider BPO services, such as claims processing, claims
management, financial and payroll management, and other administrative
services.
Furthermore, the growth of the Middle East & Africa is
attributed to the technological development in the field of medical and
healthcare industry, high penetration of advanced healthcare technologies in
research organizations such as Saudi Arabia and UAE.
Key Players
Some of the in the Global Life
Sciences BPO Market players are Accenture plc (Ireland), Boehringer
Ingelheim GmbH (Germany), Charles River Laboratories International, Inc. (US),
Covance, Inc. (US), Genpact Limited (US), Catalent, Inc. (US), Infosys (India),
Health Decisions, Inc. (US), Anthelio Healthcare Solutions (India), Cognizant
Technology Solutions (US), ProMab Biotechnologies, Inc. (US), Quintiles
Transnational Corporation (US), Paraxel International Corporation (US), Lonza Group
(Switzerland).
Segmentation
Global Life Sciences BPO Market has been segmented into
Service Type, and Application.
By Service Type, the market has been segregated into
contract research, contract manufacturing, contract sales, and marketing.
Growing focus on core activities by pharmaceutical companies, increasing the
cost of drug development, clinical trial activities, regulatory constraints are
primarily driving the market growth.
Based on the Application, the global life sciences BPO
market has been classified into medical devices and biopharma and
pharmaceuticals. The medical devices segment is expected to be the fastest
growth owing to the increasing number of medical companies opting to outsource
their strategic and non-strategic processes to vendors to improve their return
on investment (ROI), maintain profitability, product quality, and cost, and to
meet capacity constraints. Pharmaceuticals and biopharmaceuticals segment held
the largest segment in the life sciences BPO market owing to the increased
clinical trial of drugs.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity
of various industries through Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research
(CFR), and Market Research & Consulting Services.
The hydroxychloroquine drug is used in the
treatment of malaria. Apart from malaria, it is also used for the treatment of
rheumatoid arthritis, lupus erythematosus, and recently discovered
COVID-19 disease. Hydroxychloroquine is more preferable than chloroquine as it
has fewer side effects. The growth of the global hydroxychloroquine drug market
can be contributed to the growing need for rescue medication, high demand for
hydroxychloroquine drugs, due to the outbreak of COVID-19 globally, and
increasing prevalence of chronic diseases.
Hydroxychloroquine
Market Overview By Strength, By Application, By Region & Forecast to
2028.The Hydroxychloroquine Market is anticipated to grow at
a CAGR of 28% significantly. The market value is further expected to increase
up to USD 3,784.43 Million in the studied forecast period 2021-2028. Ipca is
the global manufacturer of hydroxychloroquine drugs. Sanofi S.A., Hikma
pharmaceuticals, and Concordia Healthcare are some of the competitors that
dominate the global hydroxychloroquine market. The key players are involved in
awareness campaigns, product approvals, mergers, and strategic collaborations
to strengthen their market positions. For instance, according to
outsourcing-pharma.com, on 19 May 2020, sterling pharma kicks off
hydroxychloroquine production. The US FDA recently lifted import alerts on
its plants, paving the way for the firm to export it to the US. Cadila was
already exporting it to the US, though the numbers were not huge.
Key Players
Some of the key players in
hydroxychloroquine market are Zydus Cadila (India), Ipca laboratories
(India), Sanofi S.A. (France), Hikma Pharmaceuticals (UK), Novartis
International AG (Switzerland), Teva Pharmaceutical, Industries Ltd (Israel),
Apotex Corporation (Canada), Mylan N.V. (US), Concordia Healthcare (UK), Amneal
Pharmaceuticals, Inc. (US), Taj Pharmaceuticals (India), Sun Pharmaceutical
Industries Ltd. (India), Shanghai Pharmaceuticals Holding (China), Hanlim
Pharmaceutical (South Korea), Kyung Poong (South Korea), Laurus Labs Limited
(India), Covis Pharmaceuticals, Inc. (Switzerland), Lupin Pharmaceutical
(India).
Segmentation
The hydroxychloroquine market has been
segmented by strength and application
Based on the strength, the
hydroxychloroquine market has been segmented into 200mg, 400mg, and others.
Among them, 200mg is commonly used to cure arthritis as well as for malaria and
recently for COVID-19. 400 mg dosage is commonly used for the treatment of
Malaria, Lupus Erythematosus, and Rheumatoid Arthritis once a week for the
adults. In addition, the increasing usage of hydroxychloroquine for COVID-19
treatment is driving the growth of the market.
Based on the application, the segment
is classified into Coronavirus disease (COVID 19), Malaria, Rheumatoid
Arthritis, Lupus Erythematosus, Porphyria cutanea tarda (PCT), Q fever, and
others. The malaria segment dominated the global hydroxychloroquine market and
held the largest market share in 2019. The hydroxychloroquine is used for the
treatment of malaria, which is caused by the mosquito bite. It is a reasonably
inexpensive drug and generally sold as over the counter drug in the countries
such as India.
Regional Analysis
The market has divided into regions like
the Americas, Europe, Asia-Pacific, the Middle East, & Africa. America is
further segmented into North America and Latin America. America does not
produce anti-malarial drugs, as there is no prevalence of malaria. The outbreak
of COVID-19 has increased demand. North America is predicted to be one of the
largest markets for hydroxychloroquine in the coming years. The European hydroxychloroquine
market research report has been categorized as western Europe and eastern
Europe. Western Europe further classified as Germany, France, the UK, Italy,
Spain, and the rest of western Europe. Asia-Pacific is classified as China,
India, Japan, Australia, South Korea, and the rest of Asia-Pacific. India is
the largest manufacturer of antimalarial drugs. The hydroxychloroquine market
in the Middle East & Africa is categorized into the Middle East and Africa.
About US:
Market Research Future (MRFR), enable customers to
unravel the complexity of various industries through Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Scope
The tenecteplase
drug market Share is expected to reach USD 2,455.4 million by 2030 at 5.10%
CAGR during the forecast period 2022-2030.Tenecteplase drug refers to a
recombinant enzyme that acts as a blood thinning agent. Also known as a clot
buster, tenecteplase drug helps dissolve blood clots or clumps, allowing the
blood to flow normally. These drugs are generally used for treating patients
facing heart-related issues.
Some of the leading factors influencing the market growth
include the increasing number of hypertension patients, rising number of deep
vein thrombosis cases, early aging, and sedentary lifestyles that lead to blood
clotting. The American Heart Association reported in 2017 that every 40
seconds, an individual in the United States (U.S) gets a heart attack.
Additionally, the report states that coronary heart disease
(CHD), which accounts for 43.8% is the main cause of deaths due to
cardiovascular disease (CVD) in the United States (US). Whereas, heart failure
(HF) (9.0%), high BP (9.4%), stroke (16.8%), and other CVDs (17.9%) are other
causes for deaths in the country. Furthermore, the report expects that by 2035,
over 130 million adults in the US, around 45.1%, will suffer from some form of
CVD. As a result, the overall costs of CVD are estimated to touch the valuation
of USD 1.1 trillion by 2035. Therefore, the hike in the rate of cardiovascular
diseases is projected to stimulate the tenecteplase drug market growth in the
years ahead.
Market Segmentation
The worldwide tenecteplase
drug market outlook has been segmented on the basis of application, dosage,
and end users.
The tenecteplase drug market, with respect to application,
is considered for myocardial infarction, stroke, DVT.
As per dosage, tenecteplase drug market can be broken down
into intravenous dosage and intracatheter instillation dosage.
The end-users in the market are hospitals and clinics,
surgical centers, research centers.
Regional Insight
The key markets for tenecteplase drug include Europe, Asia
Pacific, the Middle East, and Africa and North America.
North America has been estimated as the biggest market for
tenecteplase drug, on account of the rising innovations in clinical practice
and surge in myocardial infection. The region also benefits from increasing
access to stroke treatment, supported by the sophistication of healthcare
infrastructure in the region. An article by CDC in 2015 suggested that in the
United States (U.S.), close to 350,000 to 900,000 cases of Venous
thromboembolism (VTE) are estimated annually. These statistics point towards
the high potential of the tenecteplase drug market in North America.
Europe is the second most profitable market for tenecteplase
drug, with the chief reason being the increase in incidents of stroke. The
United Kingdom (UK) Organization has identified stroke as the 10th primary
cause of death globally, with 34,883 mortality cases found in the UK alone in
the year 2015. As a result of a surge in hypertension as well as high blood
pressure, the stroke cases are on the rise in the region, elevating the market
position of tenecteplase drug.
Key Companies
The key companies present in the worldwide tenecteplase drug
market include Genentec Inc., Gennova pharmaceutical, Merck Ltd., Hisun USA,
Boehringer Ingelheim International GmbH, Crunchbase Inc., Rewine
pharmaceuticals, Emcure Pharmaceutical, and others.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity
of various industries through Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research
(CFR), and Market Research & Consulting Services.